Polyp characteristics at screening colonoscopy and post-colonoscopy colorectal cancer mortality: a retrospective cohort study - 17/05/23

Abstract |
Background and Aims |
Polyp size and high-grade dysplasia in polyps at screening colonoscopy are considered risk factors for post-colonoscopy colorectal cancer (PCCRC) development and death, which might be averted by surveillance colonoscopy. However, robust evidence backing these risk factors is lacking. We aimed to investigate whether polyp size or dysplasia grade is associated with PCCRC mortality.
Methods |
This was a retrospective study including individuals of the Austrian Quality Certificate for Screening Colonoscopy who underwent a colonoscopy between January 2007 and December 2020. We investigated the association of polyp size and dysplasia in polyps with PCCRC mortality according to Cox regression analysis. In addition, whether patients with certain polyp characteristics had similar risk for CRC death compared with the Austrian population was assessed by calculating standardized mortality ratios (SMRs).
Results |
A total of 316,001 individuals were included. After a median follow-up time of 5.27 years (95% confidence interval [CI], 5.25-5.29), a significant association of polyps 10 to 20 mm (hazard ratio, 4.00; 95% CI, 2.46-6.50; P < .001) as well as high-grade dysplasia (hazard ratio, 6.61; 95% CI, 3.31-13.2; P < .001) with PCCRC death was observed. PCCRC mortality was significantly lower than the expected CRC mortality in the general population in patients with polyps < 10 mm and without high-grade dysplasia (SMR, .27; 95% CI, .21-.33; P < .001), which was not observed for patients with polyps ≥10 mm or with high-grade dysplasia (SMR, 2.05; 95% CI, 1.64-2.57; P < .001).
Conclusions |
Polyp size ≥10 mm and high-grade dysplasia are associated with PCCRC mortality in screening patients. The data suggest that these patients might benefit most from surveillance colonoscopy.
Il testo completo di questo articolo è disponibile in PDF.Abbreviations : CI, CRC, HGD, HR, ICD-10, PCCRC, SMR, SSL, WHO
Mappa
| DISCLOSURE: Dr Trauner: Advisor for Abbvie, Albireo, BiomX, BI, Falk, Gilead, Genfit, Hightide, Intercept, Janssen, MSD, Novartis, Phenex, Pliant, Regulus, Siemens, and Shire. Grants from Albireo, Alnylam, Cymabay, Falk, Gilead, Intercept, MSD, Takeda, and Ultragenyx. Travel grants from Abbvie, Falk Foundation, Gilead, Intercept, and Janssen. Speakers bureau for BMS, Falk Foundation, Gilead, Intercept, MSD, and Roche. Property rights from The Medical Universities of Graz and Vienna, which have filed patents on medical use of norUDCA (co-inventor). All other authors disclosed no financial relationships.The Main Association of Statutory Insurance Institutions, the Austrian Society for Gastroenterology and Hepatology, and the Austrian Cancer Aid are supporting the Austrian quality certificate for screening colonoscopy (Qualitätszertifikat Darmkrebsvorsorge ). |
|
| DIVERSITY, EQUITY, AND INCLUSION: We worked to ensure gender balance in the recruitment of human subjects. The author list of this paper includes contributors from the location where the research was conducted who participated in the data collection, design, analysis, and/or interpretation of the work. |
Vol 97 - N° 6
P. 1109 - giugno 2023 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
